Bank of Queensland’s result beat forecasts but brokers claim low quality, and line up to retain Sell ratings. -Bank of Queensland H1 beats on earnings -Brokers point to low quality -Management’s targets set to be lowered -Digital transformation offers execution risk By Greg Peel Brokers assume the market must have held rather underwhelming expectations for Bank of Queensland’s ((BOQ)) first half earnings result released yesterday given the surprisingly positive response in share price (+5.2%). It is true that cash earnings, which were down -33% year on year, came out better-than-expected ..read more

See Guide further below (for readers with full access). Summary: By Greg Peel Week Ending April 11, 2024. Last week the ASX200 began with a recovery from the previous week’s fall before crashing out again on hot US inflation numbers. Once again there was nothing of any great note among short position movements last week. Last week, I noted Bank of Queensland ((BOQ)) had shifted up from the 6% bracket to the 7% bracket ahead of its earnings report, which was released yesterday and led to a 5.2% share price pop. The only short position move of note last week was that of Nanosonics ((NAN)), whic ..read more

SINGAPORE, April 18, 2024 /PRNewswire/ — Finmo Tech Pte. Ltd. ("Finmo"), a Singapore-headquartered leading global payments company dedicated to delivering the world’s premier all-in-one Treasury Operating System (TOS) has announced its direct integration with Australia’s New Payment Platform (NPP) as an identified institution through its partner bank, Australian Settlements Limited (ASL), a market-leading payments pioneer. This milestone collaboration marks a milestone for ASL, to partner with a leading global fintech like Finmo to offer real-time payment (RTP) capabilities to merchants ..read more

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe. One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable qu ..read more

Potential upside as gold stocks bridge the gap to a surging gold price; plus rising rare earths price forecasts. -Operational leverage to propel lagging gold stocks higher -Potential 25% upside for the gold price over the next 6-18 months -Evolution Mining is Citi’s key pick, copper exposure a bonus -Higher rare earths forecasts over 2025, prior to 2026 deficits By Mark Woodruff  Equities to bridge the gap to rising gold prices The lagging Australian gold sector, relative to the physical gold price, will outperform over the medium-term based on the sector’s long-run tendency to outperfor ..read more

A maker of machines that make AI chips posted a weak earnings result last night, triggering selling in the space. S&P500 down -0.6%. (Available for non-subscribers after 10am) The post The Overnight Report: Reality Check appeared first on FNArena.com ..read more

Significant Scheduled Events For 18 April, 2024 The post Today’s Financial Calendar – 18-04-2024 appeared first on FNArena.com ..read more

SYDNEY, April 17, 2024 /PRNewswire/ — On April 15th, during the visit of a Chinese business delegation led by Ren Hongbin, Chairman of the China Council for the Promotion of International Trade ("CCPIT"), to Australia, the Australia-China Business Forum and the Australian roadshow ("the Roadshow") for the Second China International Supply Chain Promotion Expo ("the Expo") were held in Sydney. The Forum saw participation from over 200 representatives from both Chinese and Australian business communities. China International Exhibition Center Group Corporation Signed MoU Agreements with DMG, O ..read more

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance  The Company reports unaudited total revenue of US$114.9M[1] (AU$175.0M) an increase of 18% on the prior quarter (US$97.1M[2] or AU$148.1M). Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth ..read more

The table below ranks the 20 biggest percentage winners and losers among stocks in the ASX300 at the end of each trading day. An added filter requires sufficient daily trading volumes so that stocks with extremely low liquidity are not included. The composition of both rankings is fully automated, based on raw data. Investors are advised to find context, interpretation and background elsewhere. FNArena is not responsible for any glitches, omissions or data errors. This daily feature is not investment advice. It is offering a quick status on daily volatility for information purposes only. FNA ..read more